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Abstract
Objectives. We aimed to conduct a large audit of routine care for patients with ANCA-associated
vasculitis.
Methods. We invited all 34 hospitals within one health region in England to undertake a retrospective
case note audit of all patients newly diagnosed or treated with CYC or rituximab (RTX) for ANCA-
associated vasculitis from April 2013 to December 2014. We compared clinical practice to the British
Society for Rheumatology guidelines for the management of adults with ANCA-associated vasculitis
and the use of RTX with the National Health Service (NHS) England commissioning policy and National
Institute for Health and Care Excellence (NICE) technology appraisal.
Results. We received data from 213 patients. Among 130 newly diagnosed patients, delay from ad-
mission to diagnosis ranged from 0 to 53 days (median 6, interquartile range 3–10.5) for those diag-
nosed as inpatients. BVAS was recorded in 8% of patients at diagnosis. Remission at 6 months was
achieved in 83% of patients. The 1-year survival was 91.5%. A total of 130 patients received CYC for
new diagnosis or relapse. The correct dose of i.v. CYC (within 100 mg of the target dose calculated
for age, weight and creatinine) was administered in 58% of patients. A total of 25% of patients had an
infection requiring hospital admission during or within 6 months of completing their CYC therapy.
Seventy-six patients received RTX for new diagnosis or relapse. A total of 97% of patients met the
NHS England or NICE eligibility criteria. Pneumocystis jiroveci pneumonia prophylaxis (recommended in
the summary of product characteristics) was given in only 65% of patients.
Conclusion. We identified opportunities to improve care, including compliance with safety standards
for delivery of CYC. Development of a national treatment protocol/checklist to reduce this heterogene-
ity in care should be considered as a priority.
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Introduction
ANCA-associated vasculitis (AAV) has a high mortality,
with the greatest mortality risk occurring within the first
year after diagnosis. Yet there is very little data on the
process and outcomes of routine National Health
Service (NHS) clinical care during this time period, aside
from individual centre case series or small clinical trials.
However, the patient charity Vasculitis UK frequently
states that its members report variations in clinical prac-
tice and outcomes throughout the UK.
Remission induction of AAV with CYC is probably the
most frequent non-cancer indication for cytotoxic che-
motherapy. National guidance from the National
Chemotherapy Advisory Group, designed to ensure the
quality and safety of all chemotherapy services, is also
applicable to non-cancer chemotherapy [1]. The publica-
tion of British Society for Rheumatology (BSR) guidelines
on the management of adults with AAV [2] and an NHS
England commissioning policy for the use of rituximab
(RTX) in AAV [3], followed by a National Institute for
Health and Care Excellence (NICE) technology appraisal
[4], provided further benchmarks against which to as-
sess care.
The aim of this audit was to compare current practi-
ces, compliance with national guidelines and outcomes
within a large, representative and geographically defined
area in England.
Methods
Rheumatology units in all 34 hospitals within one of the
four health regions in England (Midlands and East, pop-
ulation 6 980 000) were invited to undertake a retro-
spective case note audit of all AAV patients who were
either newly diagnosed or treated with CYC or RTX for
relapse from April 2013 to December 2014. Each invita-
tion recommended involving the hospital’s nephrology
unit. Patients were considered to have AAV if this was
their diagnosis given by a hospital physician.
We developed and piloted a set of audit questions de-
rived from the BSR guidelines, NHS England and NICE
technology appraisal. We provided guidance on how to
identify cases through departmental database, clinic let-
ter, day-case and inpatient admissions searches. Data
were collected locally and uploaded onto a web-based
survey. Survey software was compliant with International
Organization for Standardization 27001, the internationally
recognized gold standard for information security sys-
tems, hosted by the Dudley Group NHS Foundation Trust
Clinical Audit Department. The form ensured complete
data entry for most questions, as it could not be submit-
ted unless questions were answered. Data were collected
on the specialty of the attending physician, place of diag-
nosis, date of symptom onset, admission or first clinic
appointment, diagnosis, BVAS organ systems involved,
details of remission induction, documentation of disease
activity and damage, compliance with CYC and RTX
safety standards and outcomes, including hospitalization
for infection and death. Diagnostic delay was retrospec-
tively estimated from information recorded in the medical
notes and was defined as the time from the date of the
first reported symptom attributed to AAV to the date of
diagnosis. Patient age, sex, subtype of AAV diagnosis
and ANCA type were collected later, after completion of
initial data entry.
Tertiary referral centres were defined as hospitals that
at least two other hospitals reported making tertiary
referrals to for AAV. Tertiary referral centres were com-
pared with the other non-tertiary centres using the chi-
squared test for categorical data and Wilcoxon’s rank
sum test for continuous non-normally distributed data.
The 1-year survival was calculated using the Kaplan–
Meier method. The odds ratio (OR) for infection was es-
timated using logistic regression, and the hazard ratio
(HR) for death was estimated using Cox regression;
both were adjusted for confounders (age and renal in-
volvement). Available case analysis was used where
there were missing data. Statistical analyses were per-
formed using Stata 14 statistical software (StataCorp,
College Station, TX, USA). This project was approved by
the audit department of each trust that participated.
Results
We received data about 213 patients from 20 units: 130
newly diagnosed patients and an additional 83 relapsing
patients who were treated with CYC or RTX during the
audit period. In each unit, 1–41 patients were included,
with 144 (68%) treated primarily by rheumatology and
69 (32%) treated by nephrology.
There were no missing data for audit outcomes. For
the data collected at a later stage there were some
Key messages
. Infections requiring hospital admission occurred in 25% of ANCA-associated vasculitis patients receiving
cyclophosphamide.
. Only 58% of ANCA-associated vasculitis patients on i.v. cyclophosphamide received the correct dose (within
a 10% tolerance).
. Tertiary referral centres treated ANCA-associated vasculitis sooner and more patients received correct doses of
cyclophosphamide.
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missing data [age (1%), sex (7%), diagnosis (10%) and
ANCA type (6%)].
New diagnosis
Baseline characteristics of the 130 newly diagnosed
patients are shown in Table 1. The median age was 67
years [interquartile range (IQR) 56–73], 52 patients (43%)
were female, 57 (49%) had granulomatosis with poly-
angiitis, 49 (42%) had microscopic polyangiitis, 10 (9%)
had eosinophilic granulomatosis with polyangiitis, 72
(55%) were diagnosed as inpatients and 58 (45%) were
outpatients. The frequency of organ involvement at diag-
nosis is shown in Table 2. The diagnostic delay from first
symptoms to diagnosis was a median of 2.6 months (IQR
1.2–6.1). It was shorter in those diagnosed as inpatients
[1.8 (95% CI 0.9, 3.7)] compared with outpatients [4.1
(95% CI 2.0, 12.6)]. Among inpatients, the delay from ad-
mission to diagnosis ranged from 0 to 53 days (median 6,
IQR 3–10.5). The BVAS was recorded in 10/130 patients
(8%) at diagnosis and 8/121 (7%) at 6 months. The first
choice of agent for remission induction was CYC in 99
patients (76%), RTX in 6 (5%) and other agents in 25
(19%). The prednisolone dose at treatment initiation was a
median of 55 mg (IQR 40–60, range 0–100) and additional
i.v. methylprednisolone was administered in 60 patients
(46%). At 6 months the prednisolone dose was a median
of 9.5 mg (IQR 5–10, range 0–60) among the patients
documented to be in remission. Remission at 6 months
was achieved in 101 patients (83%). The 1-year survival
was 90.8%. In the 76 patients who were recorded as hav-
ing renal involvement, 1-year survival was 85.5%.
Of the 99 newly diagnosed patients treated with CYC,
74 (75%) received i.v. doses and 25 (25%) oral. A total of
24 patients (24%) had infections requiring hospitalization
during or within 6 months of CYC treatment. The 1-year
survival in this subgroup was 87.9%. Compared with i.v.
doses, the crude OR for infection with oral CYC was 2.2
(95% CI 0.8, 6.0) and the HR for death was 2.3 (95% CI
0.8, 6.6). Once adjusted for age and renal involvement, the
OR for infection remained elevated at 1.8 (95% CI 0.6, 5.1)
and the HR for death was 1.7 (95% CI 0.5, 5.3) (Table 2).
CYC safety standards
A total of 130 patients received CYC for new diagnosis
or relapse: 101 (78%) received i.v. doses and 29 (22%)
received oral doses (Table 3). The correct dose of i.v.
CYC could be calculated for 95 (94%) of these patients
based on BSR recommendations for age, weight and re-
nal function, within a tolerance of 6100 mg, based on
the dose banding for cancer chemotherapy introduced
by NHS England, which uses dose bands within 5–10%
of the target dose [5]. The correct dose was administered
in only 50 patients (58%), with underdosing in 32 (34%)
and overdosing in 13 (8%). The most common dose
given to those who received an unrecommended dose
was 1000 mg, and those who were underdosed were on
average younger and heavier and those who were over-
dosed were on average older and lighter than the whole
cohort. At least one full blood count was checked 7–10
days after the first dose of oral or i.v. CYC in 119 patients
(92%). The total cumulative CYC dose per patient was a
median of 6 g (IQR 4–9, range 0.1–21). No patients
exceeded a lifetime exposure of 25 g. Mesna was given
in 99 patients (76%). Pneumocystis jiroveci pneumonia
(PJP) prophylaxis was given in 106 patients (82%). Thirty-
three patients (25%) had an infection requiring hospital
TABLE 1 Newly diagnosed patients (n¼130)
Characteristics Values
Age, median (IQR), years 67 (56–73)
Female 52 (43)
Male 68 (57)
GPA 57 (49)
MPA 49 (42)
EGPA 10 (9)
PR3-ANCA 52 (43)
MPO-ANCA 55 (45)
ANCA negative 9 (8)
p-ANCA only (not PR3/MPO) 3 (3)
c-ANCA only (not PR3/MPO) 1 (1)
BVAS organ system involved at diagnosis
Constitutional symptoms 88 (73)
Renal 76 (63)
Chest 62 (50)
ENT 55 (47)
Cutaneous 30 (25)
Nervous system 28 (23)
Mucous membranes/eyes 20 (17)
Abdominal 13 (11)
Cardiovascular 8 (7)
Audit outcomes
Delay from first symptom to
diagnosis, median (IQR),
months
2.6 (1.2–6.1)
BVAS recorded
At diagnosis 10 (8)
At 6 months 8 (7)
First choice of remission in-
duction treatment
CYC 99 (76)
RTX 6 (5)
Other agent 25 (19)
Glucocorticoids
Prednisolone at diagnosis,
median (IQR), mg
55 (40–60)
Additional i.v.
methylprednisolone
60 (46%)
Prednisolone at 6 months,
median (IQR), mg
10 (5–10)
Remission at 6 months 101 (83)
Survival at 1 year
All patients (n ¼ 130) 90.8% (95%
CI 84.3, 94.7)
Patients with documented
renal involvement (n ¼ 76)
85.5% (95%
CI 75.4, 91.7)
Values are n (%) unless stated otherwise. c-ANCA:
cytoplasmic ANCA; EGPA: eosinophilic granulomatosis with
polyangiitis; GPA: granulomatosis with polyangiitis; MPA:
microscopic polyangiitis; MPO: myeloperoxidase; PR3: pro-
teinase 3; p-ANCA: perinuclear ANCA.
Routine care in ANCA-associated vasculitis
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admission during or within 6 months of completing their
CYC therapy.
RTX safety standards and compliance with NICE/
NHS criteria for eligibility
A total of 76 patients received RTX for new diagnosis or
relapse (Table 4). The dosing schedule among the 16
patients newly diagnosed was 1 g  2 in 15 patients
(94%) and 375 mg/m2  4 in 1 patient (6%). The dosing
schedule among the 60 patients treated for relapse was
1 g  2 in 35 patients (58%), 375 mg/m2  4 in 16
(27%) and 1 g  1 in 7 (12%). A total of 74 patients
(97%) met NHS England or NICE eligibility criteria. PJP
prophylaxis (recommended in the summary of product
characteristics) was given in only 49 patients (65%). Igs
were checked prior to RTX in 63/68 patients (93%).
Tertiary and non-tertiary referral centres
Of the 130 newly diagnosed patients, 45 (35%) were
treated in four tertiary referral centres and 85 (65%)
were treated in 16 non-tertiary centres (Table 5). The
delay between admission and diagnosis was a median
of 4 days (IQR 2–13) in tertiary referral centres com-
pared with 7 (IQR 4–11) in non-tertiary centres (P ¼ 0.4).
The delay between diagnosis and starting immunosup-
pression was a median of 4 days (IQR 3–10) in tertiary
referral centres and 9 (IQR 3–19) in non-tertiary centres
(P ¼ 0.01). Of the 130 patients treated with CYC, 42
(32%) were treated in tertiary referral centres and 88
(68%) were treated in non-tertiary centres. The correct
dose of i.v. CYC was given in 23/32 patients (72%)
treated in tertiary referral centres compared with 29/57
patients (51%) treated in non-tertiary centres (P ¼ 0.05).
Infections requiring hospital admission occurred in 9
patients (21%) treated in tertiary referral centres com-
pared with 24 patients (27%) treated in non-tertiary
centres (P ¼ 0.5). Patients who received RTX were more
commonly treated in tertiary referral centres [48 (63%)
compared with 28 (37%) treated in non-tertiary centres].
PJP prophylaxis was prescribed to 73% of patients on
RTX treated in tertiary referral centres compared with
52% treated at non-tertiary centres (P ¼ 0.07).
Discussion
Main findings
We identified a cohort of 213 patients receiving routine
clinical care for AAV in a large health region of England.
We found long delays between admission and diagnosis
in some inpatients diagnosed with AAV (maximum >7
weeks). We found that a guideline-recommended dose of
i.v. CYC, based on age, weight and renal function, was
prescribed in <60% of patients and that adherence to
other safety standards for monitoring and prophylactic
TABLE 2 Risk of infection and death in newly diagnosed patients treated with oral compared with i.v. CYC
CYC route Infection Mortality
n (%) Crude OR for infection Adjusted ORa n (%) Crude HR for death Adjusted HRa
I.v. 15/74 (20.2) 1 1 9/74 (12.2) 1 1
PO 9/25 (36.0) 2.2 (0.8–6.0) 1.8 (0.6–5.1) 6/25 (24.0) 2.3 (0.8–6.5) 1.7 (0.5–5.3)
aAdjusted for age and renal involvement.
TABLE 3 Patients treated with CYC for new diagnosis or
relapse (n ¼ 130)
Characteristics Values
Age, median (IQR), years 65 (56–72)
Female 50 (42)
Male 68 (58)
GPA 64 (58)
MPA 39 (35)
EGPA 8 (7)
PR3-ANCA 58 (49)
MPO-ANCA 46 (39)
ANCA negative 8 (7)
p-ANCA only (not PR3/MPO) 4 (3)
c-ANCA only (not PR3/MPO) 2 (2)
Treatment
Oral CYC 29 (22)
I.v. CYC 101 (78)
Audit outcome
Correct dose of i.v. CYC,
within 100 mg
50 (58)
Underdosed >100 mg 32 (34)
Overdosed >100 mg 13 (8)
FBC was checked 7–10 days
after the first dose
119 (92)
Total cumulative dose of
CYC, median (IQR) [range], g
6 (4–9) [0.1–21]
Co-prescription of Mesna 99 (76)
Co-prescription of PJP
prophylaxis
106 (82)
Admission with infection
during or within 6 months of
CYC therapy
33 (25)
All values are n (%) unless stated otherwise. c-ANCA:
cytoplasmic ANCA; EGPA: eosinophilic granulomatosis with
polyangiitis; FBC: full blood count; GPA: granulomatosis
with polyangiitis; MPA: microscopic polyangiitis; MPO:
myeloperoxidase; PR3: proteinase 3; p-ANCA: perinuclear
ANCA.
Fiona Pearce et al.
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medication had room for improvement. RTX treatment
was prescribed to eligible patients in compliance with the
NICE technology appraisal and NHS England commis-
sioning policy, but there was opportunity to improve the
number of patients co-prescribed PJP prophylaxis as is
recommended in the summary of product characteristics.
We found that the delay between diagnosis and starting
immunosuppressive treatment and prescription of the
correct dose of CYC were significantly better in tertiary
referral centres, which provided care for much larger
numbers of patients, than non-tertiary centres.
We found that 25% of patients on CYC were admitted
with infection during or in the 6 months after CYC
treatment, which is higher than expected based on pre-
vious studies [6–8]. Our best estimates of the effect of
giving CYC orally compared with the i.v. route, once ad-
justed for the effects of age and renal involvement, were
that it increased infections by 80% and the risk of death
by 70%, but our CIs were wide, as our sample size is
small, and these were not statistically significant.
Strengths and limitations
This is the largest collaborative audit of a rare autoim-
mune rheumatic disease and the first time services for
people with AAV have been able to benchmark their
care not just against standards, but also against other
providers. Its main strength is in the large and unse-
lected group of patients who were diagnosed with AAV
by their rheumatologist or renal physician, across a
range of different-sized health care providers ranging
from smaller district general hospitals to large tertiary
referral centres. It therefore enables a representative
overview of the process and outcome of care in
England that cannot be adequately gained from existing
clinical trial reports or cohorts from single centres.
As it is an audit, there are limitations, particularly in-
complete case capture. Cases were contributed by
20 (59%) of 34 invited units. A cohort of 130 newly diag-
nosed adult patients were identified over 21 months in
an adult catchment population of 6 980 000, which
equates to an incidence rate of 10.6 per million person-
years, suggesting we identified 50% of all expected
incident cases [9], which compares favourably with the
first year of the national rheumatoid and inflammatory
arthritis audit, which captured 42% of expected cases
[10]. The demographics of cases included in the audit
were very similar to a recent epidemiological study [11]
and were received from the expected mix of district
general and tertiary referral hospitals. Data were col-
lected and entered by a large team of people, which
may lead to variations in interpretation of the questions,
however, a set of explanatory notes covering each
question minimized this risk (see supplementary data,
AAV Audit 2015 Guidance notes for completion, avail-
able at Rheumatology Advances in Practice online).
There are some missing data, particularly for baseline
demographics, as these were collected later, however,
the main outcomes have no missing data due to the
electronic form not allowing submission until all ques-
tions were answered.
The audit captured data from patients treated be-
tween April 2013 and December 2014, while the BSR,
NHS England and NICE standards were introduced dur-
ing this period, although CYC dosing guidance is identi-
cal to the 2007 guideline. This might explain the low use
of BVAS to document outcomes (which these docu-
ments recommend/require). BVAS training can be com-
pleted online [12] and the BVAS takes <3 min to
complete [13]. It is possible that care has improved
post-audit in response to these guidelines.
TABLE 4 Patients treated with RTX for new diagnosis or
relapse (n ¼ 76)
Characteristics Values
Age, median (IQR), years 50 (36–63)
Female 34 (47)
Male 39 (53)
GPA 60 (82)
MPA 11 (15)
EGPA 2 (3)
PR3-ANCA 60 (82)
MPO-ANCA 11 (15)
ANCA negative 1 (1)
p-ANCA only (not PR3/MPO) 1 (1)
c-ANCA only (not PR3/MPO) 0
Treatment
RTX given for new diagnosisa 16 (21)
Regimen
1 g  2 15 (94)
375 mg/m2  4 1 (6)
Diagnosis, %
GPA 67
MPA 33
EGPA 0
RTX given for relapse 60 (79)
Regimen
1 g  2 35 (58)
375 mg/m2  4 16 (27)
1 g  1 7 (12)
Diagnosis
GPA 95
MPA 2
EGPA 2
Audit outcomes
Treated at referral centres 48 (63)
Treated at other centres 28 (37)
Igs checked prior to treatment 63/68 (93)
Co-prescription of PJP prophylaxis 49 (65)
Met NICE technology appraisal/NHS
England eligibility criteria
74 (96)
All values are n (%) unless stated otherwise. aFirst choice
treatment (n ¼ 6), after switching (n ¼ 10). c-ANCA: cyto-
plasmic ANCA; EGPA: eosinophilic granulomatosis with poly-
angiitis; GPA: granulomatosis with polyangiitis; MPA:
microscopic polyangiitis; MPO: myeloperoxidase; PR3: pro-
teinase 3; p-ANCA: perinuclear ANCA.
Routine care in ANCA-associated vasculitis
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Real-life audit comparisons to clinical trials
Our audit is the first description of routine care of
patients with AAV and compliance with safety standards
across a large health region. The baseline characteris-
tics of included patients are similar to other UK epidemi-
ological studies from the Midlands and Norfolk [11, 14].
Our cohort also had remission (83%) [6] and survival
rates (1-year survival 90.8%) similar to other studies [8,
15–17].
Of note, our audit of routine practice found higher
rates of serious infection than in the European Vasculitis
Study Group clinical trials [18]. This is likely to be influ-
enced by the selected populations, and possibly by the
protocolized treatment, in clinical trials. For example, the
CYCLOPS trial (Randomised trial of daily oral versus
pulse Cyclophosphamide as therapy for ANCA-
associated Systemic Vasculitis) reported 11% of
patients had severe infections requiring hospital treat-
ment during a median of 18 months follow-up, so the
follow-up time was longer than in our audit, and the trial
excluded those with creatinine >500 lmol/l and age
<18 or >80 years, which are risk factors for serious in-
fection [6]. Based on these exclusion criteria alone, 7%
of the patients included in our audit would have been
excluded from the CYCLOPS trial. Our results are similar
to a recent study of all patients presenting to a single
centre, where 22% of patients receiving CYC for AAV
were admitted with infection during the first year after
commencing treatment [19]. This suggests 22–25% may
be a realistic estimate of the risk of hospitalisation with
infection in the year after starting CYC and patients
should receive counselling about pre-treatment.
We did not find a statistically significant increased risk
of infection or death in patients treated with oral com-
pared with i.v. CYC, however, our audit was underpow-
ered for this analysis. A previous meta-analysis of three
randomized controlled trials comparing oral vs i.v. CYC
found i.v. CYC conferred a significantly lower risk of in-
fection [OR 0.45 (95% CI 0.23, 0.89)] [20].
Our findings reflect some of the findings common to
rare diseases, which are highlighted in the UK Strategy
for Rare Diseases [21]. For example, people with rare
diseases are often slow to benefit from advances in
treatment [21], and it is notable that although the minor-
ity of patients (41%) overall were treated at tertiary
referral centres, the majority of patients receiving RTX
(63%) were treated in tertiary referral centres. Although
tertiary referral centres are more likely to treat severe
disease, they may also be quicker to embrace new
treatments, facilitated by these centres fulfilling the ‘spe-
cialised centre’ requirements of the NHS England policy
for access to this drug.
Clinical implications and conclusion
We identified opportunities to improve our care, includ-
ing improving compliance with safety standards for the
delivery of CYC for the 42% of patients who received an
incorrect dose of i.v. CYC. Our comparison of oral vs
i.v. CYC adds to the level of certainty from other studies
that oral CYC has greater toxicity. Development of a na-
tional treatment protocol/checklist to reduce heteroge-
neity in care should be considered as a priority. More
than half of patients were diagnosed as inpatients, and
we found a long delay between admission and diagnosis
in some patients (up to 53 days). Increased awareness
among acute admitting physicians and earlier ANCA
testing could reduce diagnostic delay and perhaps re-
duce organ damage among newly diagnosed patients.
Our finding that 25% of patients on CYC were admitted
with infection during or following CYC therapy is
higher than in clinical trials and requires increased vigi-
lance for infection and changes to the expectations
we give patients when counselling them before starting
treatment.
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